1145 ET - H. Lundbeck's $2.6 billion deal to buy Longboard Pharmaceuticals underscores the industry's growing in interest in developmental and epileptic encephalopathies, or DEEs, and rare epilepsies, analysts at Truist say. In a research note, Truist says the Longboard deal, which carries a 54% premium, has positive derivative read-throughs to the likes of Praxis Precision Medicines, Marinus Pharmaceuticals and Jazz Pharmaceuticals, all of which have drugs approved or in development for DEE. Praxis up 6.3, Marinus up 2.3% and Jazz up 1.1%. (colin.kellaher@wsj.com)
(END) Dow Jones Newswires
October 14, 2024 11:45 ET (15:45 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.